文献速递心脑血管急症

高剂量Omega-3脂肪酸与玉米油对高心血管风险患者主要不良心血管事件的影响:STRENGTH随机临床试验

Effect of High-Dose Omega-3 Fatty Acids vs Corn Oil on Major Adverse Cardiovascular Events in Patients at High Cardiovascular Risk: The STRENGTH Randomized Clinical Trial.
PubMed 文献 · JAMA · 2020-01-01
一句话结论在他汀治疗的高心血管风险患者中,加用omega-3 CA(4 g/d)与玉米油相比,主要不良心血管事件复合终点无显著差异(HR 0.99)。

STRENGTH试验是一项双盲、随机、多中心试验,纳入13 078例他汀治疗的高心血管风险、高甘油三酯血症、低HDL-C患者,随机接受omega-3 CA 4 g/d或玉米油4 g/d。主要终点为心血管死亡、非致死性心肌梗死、非致死性卒中、冠状动脉血运重建或不稳定型心绞痛住院的复合终点。omega-3 CA组胃肠道不良事件发生率更高(24.7% vs 14.7%)。结论不支持使用该omega-3脂肪酸制剂降低高危患者主要不良心血管事件。

要点

  • 该试验因中期分析显示omega-3 CA vs 玉米油临床获益概率低而提前终止(发生1384例主要终点事件,计划1600例)。
  • omega-3 CA组胃肠道不良事件发生率高于玉米油组(24.7% vs 14.7%)。
  • 结论不支持使用该omega-3脂肪酸制剂(omega-3 CA)降低高心血管风险患者的主要不良心血管事件。
  • 研究人群特征:平均年龄62.5岁,35%女性,70%糖尿病,中位LDL-C 75.0 mg/dL,中位甘油三酯240 mg/dL,中位HDL-C 36 mg/dL,中位hs-CRP 2.1 mg/L。

适用人群与场景

  • 他汀治疗的高心血管风险、高甘油三酯血症、低HDL-C患者;共13 078例,来自22个国家675个学术和社区医院。
  • 研究纳入标准:他汀治疗、高心血管风险、高甘油三酯血症、低HDL-C水平;原文未提及具体排除标准。

诊断标准与关键阈值

  • 原文未提及

处置流程与药物剂量

  • 原文未提及

红旗征与不能漏的情况

  • 原文未提及

研究设计与关键结果

  • 研究类型:双盲、随机、多中心试验(STRENGTH),纳入13 078例他汀治疗的高心血管风险患者,随机接受omega-3 CA 4 g/d(n=6539)或玉米油4 g/d(n=6539)。
  • 试验因中期分析显示omega-3 CA vs 玉米油临床获益概率低而提前终止(发生1384例主要终点事件,计划1600例)。
  • 不良事件:omega-3 CA组胃肠道不良事件发生率24.7%,玉米油组14.7%。
  • 96.6%(12 633例)完成试验并确定主要终点状态。

证据类型、等级与局限

  • 证据类型:随机双盲多中心临床试验(RCT)。
  • 局限:试验提前终止(基于中期分析显示获益概率低);原文未提及其他局限。

对床旁实践的改变

  • 原文结论不支持使用omega-3 CA(4 g/d)降低他汀治疗的高心血管风险患者的主要不良心血管事件;该结论基于与玉米油对照的比较。
  • 适用人群:他汀治疗的高心血管风险、高甘油三酯血症、低HDL-C患者;原文未提及不适用人群。
  • 常见陷阱:不能将该试验中omega-3 CA的剂量和结果外推为其他omega-3脂肪酸制剂或不同人群的推荐。

指南或共识出处

  • STRENGTH Randomized Clinical Trial(NCT02104817),发表于JAMA。

以上提炼依据论文摘要(全文未开放获取,或许可不允许翻译转载);全文请点「阅读原文」。

英文原文(摘要)· 点击展开

IMPORTANCE: It remains uncertain whether the omega-3 fatty acids eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) reduce cardiovascular risk.

OBJECTIVE: To determine the effects on cardiovascular outcomes of a carboxylic acid formulation of EPA and DHA (omega-3 CA) with documented favorable effects on lipid and inflammatory markers in patients with atherogenic dyslipidemia and high cardiovascular risk.

DESIGN, SETTING, AND PARTICIPANTS: A double-blind, randomized, multicenter trial (enrollment October 30, 2014, to June 14, 2017; study termination January 8, 2020; last patient visit May 14, 2020) comparing omega-3 CA with corn oil in statin-treated participants with high cardiovascular risk, hypertriglyceridemia, and low levels of high-density lipoprotein cholesterol (HDL-C). A total of 13 078 patients were randomized at 675 academic and community hospitals in 22 countries in North America, Europe, South America, Asia, Australia, New Zealand, and South Africa.

INTERVENTIONS: Participants were randomized to receive 4 g/d of omega-3 CA (n = 6539) or corn oil, which was intended to serve as an inert comparator (n = 6539), in addition to usual background therapies, including statins.

MAIN OUTCOMES AND MEASURES: The primary efficacy measure was a composite of cardiovascular death, nonfatal myocardial infarction, nonfatal stroke, coronary revascularization, or unstable angina requiring hospitalization.

RESULTS: When 1384 patients had experienced a primary end point event (of a planned 1600 events), the trial was prematurely halted based on an interim analysis that indicated a low probability of clinical benefit of omega-3 CA vs the corn oil comparator. Among the 13 078 treated patients (mean [SD] age, 62.5 [9.0] years; 35% women; 70% with diabetes; median low-density lipoprotein [LDL] cholesterol level, 75.0 mg/dL; median triglycerides level, 240 mg/dL; median HDL-C level, 36 mg/dL; and median high-sensitivity C-reactive protein level, 2.1 mg/L), 12 633 (96.6%) completed the trial with ascertainment of primary end point status. The primary end point occurred in 785 patients (12.0%) treated with omega-3 CA vs 795 (12.2%) treated with corn oil (hazard ratio, 0.99 [95% CI, 0.90-1.09]; P = .84). A greater rate of gastrointestinal adverse events was observed in the omega-3 CA group (24.7%) compared with corn oil-treated patients (14.7%).

CONCLUSIONS AND RELEVANCE: Among statin-treated patients at high cardiovascular risk, the addition of omega-3 CA, compared with corn oil, to usual background therapies resulted in no significant difference in a composite outcome of major adverse cardiovascular events. These findings do not support use of this omega-3 fatty acid formulation to reduce major adverse cardiovascular events in high-risk patients.

TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT02104817.

来源:JAMA,查看原文。版权归原作者所有。

参考来源

  1. Nicholls SJ, Lincoff AM, Garcia M, et al. Effect of High-Dose Omega-3 Fatty Acids vs Corn Oil on Major Adverse Cardiovascular Events in Patients at High Cardiovascular Risk: The STRENGTH Randomized Clinical Trial. JAMA. 2020. PMID: 33190147. doi:10.1001/jama.2020.22258

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。